This study investigates treatments for patients with stage III-IV melanoma, which is a type of skin cancer that has spread and cannot be removed by surgery. The focus is on patients with a specific genetic change called the BRAFV600 mutation. The study aims to find out if starting treatment with one combination of investigational medications and then switching to another can improve survival rates over two years.
Participants will undergo treatments that include investigational medications. These may involve a sequence of two different combinations of treatments. The study will compare the effectiveness of starting with one combination and then switching to another. Participants will not receive payment for their involvement.
- Who can participate: Participants must have stage III or IV melanoma with a BRAFV600 mutation. Women must not be pregnant or breastfeeding, and all participants must meet specific health criteria, including no active CNS metastases or significant autoimmune diseases.
- Study details: Participants will receive investigational medications in a specific sequence to test their effectiveness.
How understandable was the trial content above?
Hard to understand
Easy to understand
